Ben Liu
@BenjamineYLiu
co-founder and CEO @formationbio
Excited to announce our license of Gusacitinib to @sanofi for upwards of €545M in upfront and milestones in addition to royalties in the low to mid-teen based on future sales.
Enjoyed chatting with the team @a16z and @Techweek_. Not sure that Art Levinson (now @calico) remembers our call, but his advice left an indelible impact on how we think about mission, values, and cultural inertia.
If you’re building for 10+ years, “just get started” won’t cut it. @BenjamineYLiu (CEO/cofounder of @formationbio ) says: ask the counterfactual. Would the world be any different if your company didn’t exist? If not, go back to the whiteboard.
Congrats to @sanofi and @formationbio on the start of a great partnership
Excited to announce our license of Gusacitinib to @sanofi for upwards of €545M in upfront and milestones in addition to royalties in the low to mid-teen based on future sales.
Thanks @CNBC @CNBCFastMoney for having me on!
A disruptor in the AI drug discovery space... @formationbio's @BenjamineYLiu explains how his company is using AI in drug development and what's next for a quickly evolving space cnb.cx/4kYrK4X
A disruptor in the AI drug discovery space... @formationbio's @BenjamineYLiu explains how his company is using AI in drug development and what's next for a quickly evolving space cnb.cx/4kYrK4X
As AI transform drug discovery, clinical trials and drug development will be the most consequential bottleneck. Excited to be on this year's @CNBCDisruptors list as we look to build this generation's enduring pharma company.
Excited to be named to @CNBCDisruptors 50 List this year. As AI disrupts every industry, we're proud to be leading the way for drug development. cnbc.com/cnbc-disruptor…
Thrilled to welcome Mikael Dolsten, MD, PhD, former Chief Scientific Officer and President of Pfizer R&D, to Formation Bio to chair our drug picking efforts. As we look to bring together the best of pharma with the best of AI and technology, we are honored to partner with Mikael…
AI & Entrepreneurship in 2025: Are one-person billion-dollar businesses possible? @BenjamineYLiu @formationbio @dan_murphy @CNBC @kanjun @imbue_ai Mitchell Green @LeadEdgeCapital Sarah Franklin @LatticeHQ @RichardSocher @youdotcom #AI #startup #WEF25 ow.ly/HvQO50UOYWx
In Chinese culture, they call it 'eating bitterness,' Kobe Bryant called it Mamba Mentality. Read my thoughts on why we must embrace this mentality this Chinese New Year. benliu.posthaven.com/happy-chinese-…
“If we think about all the drug development activities, we think there’s a Muse for everything,” Formation Bio CEO Benjamine Liu said. “This all ladders up to a broader AI R&D scientist.” A bold claim for a big vision from Liu — but a first step here: endpts.com/sanofi-openai-…
Great example of a tangible AI use case in one of the most intractable problem areas - drug development. Congrats @formationbio
Meet Muse, our latest AI innovation for drug development—a tool designed to optimize patient recruitment built together w. @sanofi and @OpenAI. Muse is an example of how AI systems are becoming capable of performing tasks that once required entire teams or organizations.…
Meet Muse, our latest AI innovation for drug development—a tool designed to optimize patient recruitment built together w. @sanofi and @OpenAI. Muse is an example of how AI systems are becoming capable of performing tasks that once required entire teams or organizations.…
Grateful for our team @formationbio for their dedication to our mission to create this generation’s enduring pharma company and thanks @endpts for including us.
Honored to be part of @endpts list of top 11 most promising biopharmas! We're laser focused on bringing new treatments to patients faster and more efficiently by building a tech and AI driven pharma company. Join us: formation.bio/careers#job-op…